TGM2 and neoplasm: Additional studies have revealed several important SFN cancer-preventive molecular targets, including YAP/ΔNp63α signaling axis, that is inhibited by SFN to suppress cSCC tumor growth (180), and type 2 transglutaminase (TG2), the enzymatic activity of which is suppressed by covalent and irreversible binding of SFN to TG2 to inhibit the TG2-medicated maintenance of aggressive cSCC cancer phenotype (206).